Walgreens Struggling to Improve Profitability
We think investors should exercise caution as the firm’s strategy has yet to bear fruit.
Vishnu Lekraj: Walgreens reported results this morning that continue to show the firm struggling to improve its profitability. Over the past several years, the firm has pursued a strategy where it's trying to be a preferred pharmacy at many PBM narrow networks. This has led the firm to receive some discounted pricing from PBMs, which has pressured profitability in the back end of the store.
In order to offset this trend, the firm has tried to drive sales of front-end products, which consist of convenience goods and health products. However, this strategy has yet to bear fruit, as front-end sales have decreased ever quarter over the past several years. We are concerned about this trend, but this falls in line with the long term thesis for the retail pharmacy. We are reaffirming our no moat rating for the firm, and our $73 fair value estimate. Thus, we believe investors should look at the firm cautiously and hold the stock if they still own it.
Vishnu Lekraj does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.